Pfizer, Inc. (NYSE:PFE) was the target of a significant growth in short interest during the month of September. As of September 15th, there was short interest totalling 50,665,014 shares, a growth of 12.4% from the August 31st total of 45,068,122 shares. Approximately 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 20,991,377 shares, the short-interest ratio is presently 2.4 days.

Shares of Pfizer (PFE) opened at 36.00 on Friday. The firm has a market capitalization of $214.10 billion, a price-to-earnings ratio of 26.34 and a beta of 1.00. The stock has a 50 day moving average of $34.63 and a 200 day moving average of $33.68. Pfizer has a 52-week low of $29.83 and a 52-week high of $36.24.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the previous year, the firm earned $0.64 EPS. The business’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts predict that Pfizer will post $2.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.56%. Pfizer’s payout ratio is currently 94.12%.

Several research analysts recently issued reports on the stock. Morgan Stanley reissued a “neutral” rating and set a $35.00 price target (down from $38.00) on shares of Pfizer in a report on Monday, June 12th. Jefferies Group LLC reissued a “neutral” rating and set a $34.00 price target on shares of Pfizer in a report on Friday, June 16th. BidaskClub raised shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Friday, June 23rd. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a report on Monday, July 10th. Finally, Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a report on Friday, July 14th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and thirteen have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $38.21.

In other news, CEO Ian C. Read sold 96,950 shares of the company’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $34.00, for a total value of $3,296,300.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the sale, the insider now directly owns 145,649 shares of the company’s stock, valued at $5,097,715. The disclosure for this sale can be found here. Insiders sold 464,521 shares of company stock valued at $15,813,961 over the last ninety days. Corporate insiders own 0.06% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Northstar Group Inc. raised its holdings in shares of Pfizer by 0.4% in the 2nd quarter. Northstar Group Inc. now owns 8,602 shares of the biopharmaceutical company’s stock worth $289,000 after purchasing an additional 35 shares in the last quarter. Peregrine Asset Advisers Inc. raised its holdings in shares of Pfizer by 0.5% in the 2nd quarter. Peregrine Asset Advisers Inc. now owns 7,354 shares of the biopharmaceutical company’s stock worth $247,000 after purchasing an additional 35 shares in the last quarter. Northwest Quadrant Wealth Management LLC raised its holdings in shares of Pfizer by 0.8% in the 2nd quarter. Northwest Quadrant Wealth Management LLC now owns 6,329 shares of the biopharmaceutical company’s stock worth $211,000 after purchasing an additional 50 shares in the last quarter. River Wealth Advisors LLC raised its holdings in shares of Pfizer by 0.3% in the 2nd quarter. River Wealth Advisors LLC now owns 15,818 shares of the biopharmaceutical company’s stock worth $531,000 after purchasing an additional 55 shares in the last quarter. Finally, Meridian Wealth Management LLC raised its holdings in shares of Pfizer by 0.5% in the 2nd quarter. Meridian Wealth Management LLC now owns 11,966 shares of the biopharmaceutical company’s stock worth $402,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 69.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/pfizer-inc-pfe-short-interest-update/1611400.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.